Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III products.
Immunocore has appointed Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer. Mohammed Dar will lead the continued clinical development of tebentafusp(IMCgp100) and other key programmes in Immunocore’s pipeline.
https://european-biotechnology.com/wp-content/uploads/2024/04/mdar.jpg250250h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-05-13 14:18:002019-05-13 14:18:00Immunocore appoints Mohammed Dar
Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
Medica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain as Chief Executive Officer until Dr Quin joins the company.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_2019_Medica_Group_Dr_Stuart_Quin.jpg750750h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-05-12 16:31:442019-05-12 16:31:44Dr Stuart Quin appointed as CEO of Medica Group
Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
https://european-biotechnology.com/wp-content/uploads/2024/04/EBM_Ethikrat.jpg450850Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-10 06:46:512019-05-10 06:46:51Ethics Council calls for moratorium of clinical germline manipulation
Immunotherapy and infection specialist BioNTech SE (Mainz, Germany) has acquired preclinical and clinial antibody assets and infrastructior from MabVax Therapeutics Holding, Inc.
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
With partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2019_timothydyer.jpg5631000h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-05-07 13:03:002019-05-07 13:03:00Lessons from a former poster child
The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
https://european-biotechnology.com/wp-content/uploads/2024/04/Confo.jpeg18752500Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-07 10:45:382019-05-07 10:45:38Confo Therapeutics raise €30m in Series A financing
Philogen SpA raises €62m to push registration
Latest NewsPrivately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III products.
Immunocore appoints Mohammed Dar
AppointmentsImmunocore has appointed Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer. Mohammed Dar will lead the continued clinical development of tebentafusp(IMCgp100) and other key programmes in Immunocore’s pipeline.
Halt of Polyphor trial shrinks company valuation
Latest NewsRoche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
Dr Stuart Quin appointed as CEO of Medica Group
AppointmentsMedica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain as Chief Executive Officer until Dr Quin joins the company.
Ethics Council calls for moratorium of clinical germline manipulation
Latest NewsFollowing the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
BioNtech aquires antibody assets from MabVax Therapeutics
Latest NewsMS linked to epigenetic changes in immune cells
Latest NewsEpigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Whitepaper Spotlight: Proactive Biomarker Planning to Optimize Clinical Trials
Sponsored PublicationsOncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
Lessons from a former poster child
OpinionWith partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.
Confo Therapeutics raise €30m in Series A financing
Latest NewsThe round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.